Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Simei Shi"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background The prognostic value of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) has been extensively studied and verified by the CellSearch® system. Varieties of microfluidic systems have been developed to improve captur
Externí odkaz:
https://doaj.org/article/b73ad06a859b45e080115653b8b18d36
Publikováno v:
BMC Nursing, Vol 22, Iss 1, Pp 1-8 (2023)
Abstract Background During immunotherapy treatment and survival, identifying symptoms requires a standardized and validated assessment tool. The aim of this study was to translate, validate and use the Chinese version of the Immunotherapy of the M.D.
Externí odkaz:
https://doaj.org/article/93e8572cac3846dabc86519b8cd463f2
Publikováno v:
BMC Palliative Care, Vol 21, Iss 1, Pp 1-10 (2022)
Abstract Background Little is known about patients’ intention for participation in end-of-life decisions (EOLD) in three coastal provinces in southern China. This study aimed to explore the willingness of patients with cancer pain to participate in
Externí odkaz:
https://doaj.org/article/ae8addfda63048629b75a2b3699d88f5
Publikováno v:
Chinese Journal of Integrative Nursing. 9:212-214
MDASI Immunotherapy for Early-Phase Trials Module: Validation and Application of the Chinese Version
Objectives: To translate, validate and use the Chinese version of the Immunotherapy of the M.D. Anderson Symptom Inventory for Early-Phase Trials module (MDASI-Immunotherapy EPT) to assess the symptom burden of cancer patients receiving immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdc80af096112434c30ec543cb69344c
https://doi.org/10.21203/rs.3.rs-2128873/v1
https://doi.org/10.21203/rs.3.rs-2128873/v1
Publikováno v:
Medicine. 96:e8062
Recruitment rate of clinical trials in cancer patients is pretty low in China. Little is known about factors influencing trial recruitment in Chinese cancer patients. The aim of present study is to evaluate the barriers and facilitators to participat
Autor:
Simei Shi, Li-Xia Peng, Xinjian Li, Hongbing Huang, Li-Sheng Zheng, C.N. Qian, Tie Jun Huang, Qiaoqiao Chu, Li Cao, Bi-Jun Huang, Liang Xu, Shi-Jun Zhang, Jialing Huang
Publikováno v:
Cell Death & Disease
Serglycin is a proteoglycan that was first found to be secreted by hematopoietic cells. As an extracellular matrix (ECM) component, serglycin promotes nasopharyngeal carcinoma (NPC) metastasis and serves as an independent, unfavorable NPC prognostic
Publikováno v:
Medicine; 9/15/2017, Vol. 96 Issue 37, p1-4, 4p, 3 Charts